SEARCH

SEARCH BY CITATION

References

  • 1
    Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001; 357: 10934.
  • 2
    Kirschner BS. Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Neth J Med 1998; 53: S138.
  • 3
    Ganguli SC, Cawdron R, Irvine EJ. Alternative medicine use by Canadian ambulatory gastroenterology patients: secular trend or epidemic? Am J Gastroenterol 2004; 99: 31926.
    Direct Link:
  • 4
    Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005; 11: 28795.
  • 5
    Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med 2000; 8: 8896.
  • 6
    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 24652.
  • 7
    Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280: 156975.
  • 8
    Thomas KJ, Coleman P, Nicholl JP. Trends in access to complementary or alternative medicines via primary care in England: 1995-2001 results from a follow-up national survey. Fam Pract 2003; 20: 5757.
  • 9
    Day AS. Use of complementary and alternative therapies and probiotic agents by children attending gastroenterology outpatient clinics. J Paediatr Child Health 2002; 38: 3436.
  • 10
    Day AS, Whitten KE, Bohane TD. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J Paediatr Child Health 2004; 40: 6814.
  • 11
    Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: 13841.
  • 12
    Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002; 8: 1749.
  • 13
    Moody GA, Eaden JA, Bhakta P, Sher K, Mayberry JF. The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health 1998; 112: 26971.
  • 14
    Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986; 27: 8268.
  • 15
    Verhoef MJ, Sutherland LR, Brkich L. Use of alternative medicine by patients attending a gastroenterology clinic. CMAJ 1990; 142: 1215.
  • 16
    Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: an Internet survey. Can J Gastroenterol 1999; 13: 32732.
  • 17
    Rawsthorne P, Shanahan F, Cronin NC, et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1298303.
    Direct Link:
  • 18
    Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol 2004; 99: 88993.
    Direct Link:
  • 19
    Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003; 98: 15638.
    Direct Link:
  • 20
    Markowitz JE, Mamula P, DelRosario JF, et al. Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 599605.
  • 21
    Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 6359.
  • 22
    Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 161723.
  • 23
    Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B. Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease. BMC Complement Altern Med 2006; 6: 19.
  • 24
    Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001; 9: 211.
  • 25
    Thompson T, Feder G. Complementary therapies and the NHS. BMJ 2005; 331: 8567.
  • 26
    Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 3828.
    Direct Link:
  • 27
    Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr 2003; 36: 4649.
  • 28
    Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 697701.
    Direct Link:
  • 29
    Ernst E. Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence. Eur J Pediatr 2003; 162: 7280.
  • 30
    Angell M, Kassirer JP. Alternative medicine – the risks of untested and unregulated remedies. N Engl J Med 1998; 339: 83941.
  • 31
    Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 220011.
  • 32
    Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile-onset Crohn’s disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001; 13: 143947.
  • 33
    Otley A, Verhoef MJ, Best A. Prevalence and determinants of use of complementary and alternative medicine in a Canadian pediatric inflammatory bowel disease population. Gastroenterology 2001; 120: A213.
  • 34
    Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health (Oxf) 2004; 26: 1527.
  • 35
    Green TJ, Issenman RM, Jacobson K. Patients’ diets and preferences in a pediatric population with inflammatory bowel disease. Can J Gastroenterol 1998; 12: 5449.
  • 36
    Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 2004; 23: 16170.
  • 37
    Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996; 334: 155760.
  • 38
    Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 73947.
  • 39
    Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 1996; 40: 5039.
  • 40
    Quattropani C, Ausfeld B, Straumann A, Heer P, Seibold F. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 2003; 38: 27782.
  • 41
    Spigelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. Pediatrics 1994; 94: 8114.
  • 42
    Armitage EL, Aldhous MC, Anderson N, et al. Incidence of juvenile-onset Crohn’s disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004; 127: 10517.
  • 43
    Verhoef MJ, Scott CM, Hilsden RJ. A multimethod research study on the use of complementary therapies among patients with inflammatory bowel disease. Altern Ther Health Med 1998; 4: 6871.
  • 44
    Hayden CW, Bernstein CN, Hall RA, Vakil N, Garewal HS, Fass R. Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD). Dig Dis Sci 2002; 47: 18.
  • 45
    Day AS, Whitten KE, Bohane TD. Childhood inflammatory bowel disease: parental concerns and expectations. World J Gastroenterol 2005; 11: 102831.
  • 46
    Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 18548.
  • 47
    American Academy of Pediatrics. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics 2001; 107: 598601.